The Technical Analyst
BiondVax Pharmaceuticals [BVXV]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
BiondVax Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.74% ILS1.360
America/New_York / 6 sep 2023 @ 15:59
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 4.97 mill |
| EPS: | -2.35 |
| P/E: | -0.579 |
| Earnings Date: | Nov 29, 2023 |
| SharesOutstanding: | 3.65 mill |
| Avg Daily Volume: | 0.0389 mill |
| RATING 2023-10-03 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 1/22 | 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | |
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.579 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.10x |
| Company: PE -0.579 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
ILS 0.745 - 0.855 ( +/- 6.88%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-01-01 | Margolin Yael | Sell | 133 200 | Restricted Share Units |
| 2023-01-01 | Margolin Yael | Sell | 0 | Ordinary Shares |
| 2023-01-01 | Laster Morris C | Sell | 133 200 | Restricted Share Units |
| 2023-01-01 | Laster Morris C | Sell | 0 | Ordinary Shares |
| 2023-01-01 | Lowell George | Sell | 133 200 | Restricted Share Units |
| INSIDER POWER |
|---|
| -100.00 |
| Last 23 transactions |
| Buy: 0 | Sell: 12 745 600 |
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | ILS1.360 (0.74% ) |
| Volume | 0.0227 mill |
| Avg. Vol. | 0.0389 mill |
| % of Avg. Vol | 58.21 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For BVXV
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
BVXV
BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.
Last 10 Buy Signals
Latest Press Releases
2023-09-06 06:00:00 - Press Release
Biondvax Pharmaceuticals Ltd. Rebrands As Scinai Immunotherapeutics Ltd.
Scinai immunotherapeutics to debut tomorrow under nasdaq ticker symbol “scni” scinai immunotherapeutics to debut tomorrow under nasdaq ticker symbol “scni”
2023-08-11 09:00:00 - Press Release
Biondvax Reports Second Quarter Financial Results And Provides Business Update
Jerusalem, aug. 11, 2023 (globe newswire) -- via ibn - biondvax pharmaceuticals ltd. (nasdaq: bvxv), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, announced the publication today of its financial results for the second quarter ended june 30, 2023, and provided a business update.
2023-08-01 16:01:00 - Press Release
Nasdaq Grants Biondvax Extension To Regain Compliance With Listing Rules
Jerusalem, aug. 01, 2023 (globe newswire) -- via ibn -- biondvax pharmaceuticals ltd. (nasdaq: bvxv), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today announced that nasdaq reviewed biondvax's multi-faceted plan to regain compliance with nasdaq's listing rule 5550(b) and provided it an extension until october 30, 2023, to demonstrate compliance.
2023-03-16 13:10:00 - Press Release
Biondvax To Present At Bio-europe Spring
Jerusalem, march 16, 2023 (globe newswire) -- via investorwire – biondvax pharmaceuticals ltd . (nasdaq: bvxv), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, announces today that its ceo amir reichman will be presenting in-person at the 17th annual bio-europe spring taking place march 20–22, 2023, in basel, switzerland. the event is expected to bring together over 2,800 executives from biotech, pharma and finance companies to engage in 15,000+ one-to-one meetings.
2023-02-02 14:15:00 - Press Release
Biondvax Presenting At Bio Ceo & Investor Conference
Jerusalem, feb. 02, 2023 (globe newswire) -- via investorwire – biondvax pharmaceuticals ltd . ( nasdaq: bvxv ), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, announced today that its ceo amir reichman will present at the bio ceo & investor conference . the conference is taking place feb. 6-9, 2023, in new york.
Latest News
2023-03-16 13:10:00 - GlobeNewsWire
BiondVax to Present at BIO-Europe Spring
JERUSALEM, March 16, 2023 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd . (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, announces today that its CEO Amir Reichman will be presenting in-person at the 17th annual BIO-Europe Spring taking place March 20–22, 2023, in Basel, Switzerland. The event is expected to bring together over 2,800 executives from biotech, pharma and finance companies to engage in 15,000+ one-to-one meetings.
2023-02-02 14:15:00 - GlobeNewsWire
BiondVax Presenting at BIO CEO & Investor Conference
JERUSALEM, Feb. 02, 2023 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd . ( Nasdaq: BVXV ), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, announced today that its CEO Amir Reichman will present at the BIO CEO & Investor Conference . The conference is taking place Feb. 6-9, 2023, in New York.
2023-01-23 09:28:30 - PennyStocks
Best Penny Stocks To Buy? 5 To Watch After Big News This Week
Penny stocks to watch with news that are turning heads in the stock market this week. The post Best Penny Stocks To Buy?
2022-11-21 06:00:00 - PRNewsWire
BiondVax CEO to Present at the January 2023 Biotech Showcase in San Francisco
JERUSALEM , Nov. 21, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) ("BiondVax"), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, announced today that its CEO Amir Reichman will present at the January 9-11, 2023 Biotech Showcase conference.
2022-11-03 11:30:00 - PRNewsWire
BiondVax to present at Recent Advances in Fermentation Technology (RAFT) 14 Conference
JERUSALEM , Nov. 3, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) ("BiondVax"), a biotechnology company focused on developing, manufacturing, and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, announced today that Dr. Dalit Weinstein Fischer , BiondVax's Head of Technical R&D, will attend and present at Recent Advances in Fermentation Technology (RAFT) 14, a conference of the Society for Industrial Microbiology and Biotechnology (SIMB) taking place November 6 to 9, 2022 in Orlando, Florida.
2022-10-18 07:55:00 - Newsfile Corp
BiondVax to Present at LD Micro Investor Conference in Los Angeles
Jerusalem, Israel--(Newsfile Corp. - October 18, 2022) - BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) ("BiondVax"), a biotechnology company focused on developing, manufacturing, and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, announced today that Joshua Phillipson, BiondVax's Director of Investor Relations, will attend and present at the LD Micro Main Event XV, an investor conference taking place October 25 to 27, 2022 in Los Angeles.
2022-10-11 14:00:00 - PRNewsWire
BiondVax to present at LD Micro Investor Conference in Los Angeles
JERUSALEM , Oct. 11, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) ("BiondVax"), a biotechnology company focused on developing, manufacturing, and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, announced today that Joshua Phillipson, BiondVax's Director of Investor Relations, will attend and present at the LD Micro Main Event XV, an investor conference taking place October 25 to 27, 2022 in Los Angeles.
2022-09-08 09:13:00 - PRNewsWire
BiondVax to Present at H.C. Wainwright 24th Annual Global Investment Conference
2022-05-09 06:00:00 - PRNewsWire
BiondVax to Present at this week's Biomed Israel Conference
JERUSALEM , May 9, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, today announced that it will present at the 20th Biomed Israel Conference and Exhibition, to be held May 10-12, 2022, in Tel Aviv, Israel.
2022-04-04 15:23:08 - Seeking Alpha
BiondVax Pharmaceuticals Ltd. (BVXV) CEO Amir Reichman on Q4 2021 Results - Earnings Call Transcript
BiondVax Pharmaceuticals Ltd. (BVXV) CEO Amir Reichman on Q4 2021 Results - Earnings Call Transcript